Cargando…

Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1)

Background: Semaglutide is a long-acting, subcutaneous (s.c.), glucagon-like peptide-1 analogue that is currently being investigated for obesity management in adults with overweight or obesity in the phase 3 STEP clinical trial program. Varying degrees of weight loss were observed with once-weekly s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kushner, Robert F, Garvey, W Timothy, Hesse, Dan, Koroleva, Anna, Lim, Soo, Lingvay, Ildiko, Mosenzon, Ofri, Wallenstein, Signe O R, Wadden, Thomas A, le Roux, Carel W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Adipose Tissue, Appetite, and Obesity
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089676/ http://dx.doi.org/10.1210/jendso/bvab048.046

Ejemplares similares

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)
por: Rubino, Domenica M, et al.
Publicado: (2021)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

Abstract 9: Once-weekly subcutaneous semaglutide 2.4 mg reduces body weight in adults with overweight or obesity regardless of baseline characteristics (STEP 1)
por: Suresh, Swaroop H, et al.
Publicado: (2022)

Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study
por: Wilding, John P H, et al.
Publicado: (2021)

RF24 | PSUN116 Once-weekly semaglutide delays a late phase gastric emptying of solid meal measured by repeated scintigraphic imaging in obese women with PCOS
por: Jensterle, Mojca, et al.
Publicado: (2022)

Safety and Tolerability of Concomitant Administration of Multiple-Dose AM833 With Semaglutide 2.4 MG for Weight Management
por: Enebo, Lone B, et al.
Publicado: (2021)

Preclinical Weight Loss Efficacy of AM833 in Combination With Semaglutide in Rodent Models of Obesity
por: John, Linu M, et al.
Publicado: (2021)

No Differences in Metabolic Parameters Between Roux-en-Y Gastric Bypass and Sleeve Gastrectomy, Regardless of Achieved Weight Loss
por: Holanda, Narriane Chaves Pereira, et al.
Publicado: (2021)

Once-Weekly Exenatide Enhances Weight Loss Maintenance in Adolescents with Severe Obesity: A Randomized, Placebo-Controlled Trial
por: Fox, Claudia K, et al.
Publicado: (2021)

MON-120 Effect of Weight Loss on Physical Function Measured by the 6-Minute Walking Distance Test in Individuals with Obesity: Results from the SCALE IBT Trial of Liraglutide 3.0 Mg
por: Rubino, Domenica, et al.
Publicado: (2019)

SAT-099 Liraglutide 3.0 mg as an Adjunct to Intensive Behavior Therapy in Individuals with Obesity: SCALE IBT 56-Week Randomized, Double-Blind, Placebo-Controlled Trial
por: Wadden, Thomas, et al.
Publicado: (2019)

SAT-105 Weight Loss As Determined By Adherence To Reduced Caloric Diet, Increased Physical Activity, Liraglutide 3.0 Mg and Placebo: A Sub-analysis Of The SCALE IBT Trial
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

Insulin Resistance Moderates the Association Between BMI and Metabolic Syndrome Severity in Women 4–10 Years After Pregnancy, Independent of Gestational Diabetes Status
por: Callahan, Makenzie, et al.
Publicado: (2021)

SAT658 Tirzepatide Reduces The Predicted Risk Of Developing Atherosclerotic Cardiovascular Disease: A Post-hoc Analysis Of The Surmount-1 Trial
por: Hankosky, Emily R, et al.
Publicado: (2023)

OR04-05 MYOD1 Is Associated with Eosinophil-Mediated Browning of Subcutaneous Adipose Tissue
por: Li, Ting, et al.
Publicado: (2020)

Laminin-α4 Is Uniquely Upregulated in Subcutaneous White Adipose Tissue in Murine and Human Models of Obesity
por: Goddi, Anna, et al.
Publicado: (2021)

MON-118 Biochemical and Clinical Correlates of Subcutaneous Adipose mRNA Transcript Levels in Men with T2DM
por: Tun, Nyo Nyo, et al.
Publicado: (2019)

OR01-4 Mast Cells and Human Adipose Beiging: Mast Cells Are Recruited to Subcutaneous White Adipose and Degranulate in Response to Cold
por: Kern, Philip, et al.
Publicado: (2019)

SUN-LB106 The Transcriptomic Evidences on Role of Abdominal Visceral vs. Subcutaneous Adipose Tissue in the Pathophysiology of Diabetes in Asian Indian Indicates the Involvement of Both
por: Mathur, Sandeep Kumar, et al.
Publicado: (2020)

MON-598 Vitamin B12 Deficiency Leads to Fatty Acid Metabolism Dysregulation and Increased Pro-Inflammatory Cytokine Production in Human Adipocytes and Maternal Subcutaneous and Omental Adipose Tissue
por: Samavat, Jinous, et al.
Publicado: (2020)

SUN-091 Functional Links between ADP-Ribosylation and Phosphorylation on Histone H2B Regulate Adipocyte Differentiation
por: Huang, Dan, et al.
Publicado: (2019)

PSUN83 Exploring the Role of PARP1-mediated ADP-ribosylation in Diet-induced Obesity
por: Lee Kraus, W, et al.
Publicado: (2022)

OR23-5 Exploring the Role of PARP7 in Adipogenesis
por: Lee Kraus, W, et al.
Publicado: (2022)

SUN-LB101 NRF2 Represses Obesity-Associated Adipose Tissue Inflammation in Mice
por: Yagishita, Yoko, et al.
Publicado: (2020)

FRI011 Exploring The Contribution Of PARP1-mediated Site-specific ADP-Ribosylation Of C/EBPb In Macrophages To Diet-induced Obesity
por: Whitaker, Amy L, et al.
Publicado: (2023)

FRI019 Mono(ADP-Ribosyl)ation Of Ribosomal Proteins During Adipogenesis
por: Tan, Xinrui, et al.
Publicado: (2023)

SUN-595 Comparative Comorbidity Burden Among Patients with Prader-Willi Syndrome: A Population-Level Cohort Study
por: Stafford, Diane E J, et al.
Publicado: (2020)

SUN-604 U.S. Prevalence & Mortality of Prader-Willi Syndrome: A Population-Based Study of Medical Claims
por: McCandless, Shawn E, et al.
Publicado: (2020)

SUN-597 Healthcare Utilization Patterns Among Commercially Insured Patients with Prader-Willi Syndrome: A Retrospective Analysis of Administrative Claims
por: Butler, Merlin G, et al.
Publicado: (2020)

Hair Cortisol, Obesity and the Immune System: Results From a 3 Year Longitudinal Study
por: van der Valk, Eline S, et al.
Publicado: (2021)

SAT-LB020 Use of Ultrasound to Characterize Abdominal Adipose Tissue Distribution and Its Impact on Metabolic Syndrome
por: Cuatrecasas Cambra, Guillem, et al.
Publicado: (2019)

MON-099 Age-Related Differences in Appetite Regulation among Adults with Obesity: More Than Just Hunger and PYY and Ghrelin? Oh My!
por: Iwamoto, Sean, et al.
Publicado: (2019)

MON-101 The LD Lync Study: Natural History Study of Lipodystrophy Syndromes: Early Lessons from the Pilot Data
por: Jalal Eldin, Abdelwahab, et al.
Publicado: (2019)

MON-114 Effect of Selective Mineralocorticoid Receptor Antagonist on liver Fat and Metabolism in Patients with Type 2 Diabetes: A Randomized Controlled Trail
por: Kistorp, Caroline, et al.
Publicado: (2019)

MON-092 Role of Genetic Variants of NNMT rs694539 and rs1941404, FTO rs1421085 and Irx3 rs3751723 Polymorphisms on Resting Energy Expenditure and BMI
por: Bañales Luna, Maciel, et al.
Publicado: (2019)

MON-113 Taste Sensitivity is Related to Incretin Response to Oral Glucose Challenge, Dietary Habits and Body Composition: A Novel Link with Energy Metabolism
por: Dagdelen, Selcuk, et al.
Publicado: (2019)

MON-106 Prevalence of Abdominal Obesity According to Different Cutoff Points in the Peruvian Population Living at Different Altitudes
por: Pajuelo-Ramirez, Jaime, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pv3pekokvrn60u0ehpj7s5qnqs